News Search Results
Jul 07, 2025, 10:31 ET World-Class, Turnkey Cro Facility Available Through Bankruptcy Sale with Full Suite of Lab Equipment & Intellectual Property
features sophisticated infrastructure and enhanced security for sensitive operations. Engineered to support the development of pharmaceuticals, biotechnology products and medical devices, the facility's integrated laboratories are designed to deliver toxicology, safety pharmacology and bioanalytic characterization
More news about: Hilco Global
Jul 07, 2025, 10:15 ET Biochip Market to Reach USD 17.99 Billion by 2030 -- Driven by Diagnostics, Personalized Medicine, and Drug Discovery | Valuates Reports
July 7, 2025 /PRNewswire/ -- Biochip Market is Segmented by Type (Microarrays, Microfluidics), by Application (Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostics Centers, Academic & Research Institutes).
More news about: Valuates Reports
Jul 07, 2025, 10:01 ET Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
patients benefit from safer, more effective therapies. Understanding the Platform Calidi Biotherapeutics is clinical stage biotechnology company that is developing genetic medicines and proprietary genetically engineered oncolytic viruses. Calidi's RedTail systemic antitumor virotherapy
More news about: NetworkNewsWire
Jul 07, 2025, 08:30 ET Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
patients benefit from safer, more effective therapies. Understanding the Platform Calidi Biotherapeutics is clinical stage biotechnology company that is developing genetic medicines and proprietary genetically engineered oncolytic viruses. Calidi's RedTail systemic antitumor virotherapy
More news about: NetworkNewsWire
Jul 07, 2025, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
employees vesting over four years with a one-year cliff. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Jul 07, 2025, 01:00 ET Nuevocor Strengthens Board with Appointment of Thierry Abribat
-- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry
More news about: Nuevocor
Jul 04, 2025, 11:30 ET Digital Twin Market Size to hit USD 140.93 billion by 2031, Experiences Growth Due to Increasing Adoption of IoT Devices, Large-Scale Digital Transformation | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 04, 2025, 10:50 ET Printed Electronics Market Size to Reach USD 60.18 Billion by 2031, Experiences Growth Owing to the Technological Advancements and Increasing Demand across Sectors | Report by The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 04, 2025, 10:30 ET Wearable EEG Devices Market Size to Grow by USD 695.51 million by 2031, Experiences Growth Owing to Growing Prevalence of Neurological Disorders | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 04, 2025, 09:30 ET HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
BOSTON, July 4, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory
More news about: HotSpot Therapeutics
Jul 03, 2025, 20:30 ET Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today
More news about: Brii Biosciences Limited
Jul 03, 2025, 16:04 ET Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, announces the acceptance for publication of a research article entitled "Liposomal-Cannabidiol Injection: Preliminary Insights into
More news about: Innocan Pharma Corporation
Jul 03, 2025, 16:01 ET Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, announces the acceptance for publication of a research article entitled "Liposomal-Cannabidiol Injection: Preliminary Insights into
More news about: Innocan Pharma Corporation
Jul 03, 2025, 14:15 ET RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
[email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit
More news about: Robbins Geller Rudman & Dowd LLP
Jul 03, 2025, 13:49 ET Dr. Aubrey de Grey Brings Cutting-Edge Science to RAADfest 2025: LEV Foundation Partners with Coalition for Radical Life Extension
nonprofit organization founded by Dr. Aubrey de Grey to accelerate the development and deployment of rejuvenation biotechnology. The Foundation focuses on damage repair approaches to aging and conducting combination therapy studies that demonstrate significant life extension
More news about: LEV Foundation
Jul 03, 2025, 11:30 ET Photovoltaic Market Size to Reach USD 1,145.70 billion by 2031, Experiences Increasing Demand for Solar Panels | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 03, 2025, 11:15 ET Secure Logistics Market Size Grows to USD 84.39 Billion by 2031 | CAGR of 5.2% | Exclusive Report by The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 03, 2025, 08:30 ET Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results
Company's industry influence. About Zhengye Biotechnology Holding Limited Through Jilin Zhengye Biological Products Co., Ltd., the Company's operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development,
More news about: Zhengye Biotechnology Holding Limited
Jul 03, 2025, 07:40 ET SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP
Jul 03, 2025, 07:30 ET INOVIO Announces Pricing of $25 Million Public Offering
Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Jul 02, 2025, 21:30 ET Probiotics in Animal Feed Market worth $8.27 billion by 2030- Exclusive Report by MarketsandMarkets™
overall well-being of animals, responding to both regulatory pressures and consumer demand for safer, more sustainable animal products. Advances in biotechnology have enabled the development of more effective, species-specific probiotic formulations, further driving their adoption across poultry, swine, cattle,
More news about: MarketsandMarkets
Jul 02, 2025, 21:09 ET 晶泰科技戰略投資MIT精英團隊Foundry Bio,生成式AI重塑萬億抗衰市場
RNA 引導系統、蛋白質工程和合成生物學技術。他做為第一作者的研發成就包括首個真核 RNA 引導 DNA 核酸酶、高靈敏度哺乳動物細胞狀態傳感器，以及同類最佳（best in class）的 AI 指導的少樣本蛋白工程模型；相關成果發表於《Nature》《Science》《Nature Biotechnology》《Nature Materials》等頂刊，促成六項國際專利並催生了三家初創公司。姜凱議目前在普林斯頓大學生物工程系擔任教職，是該系歷史上未經博士後訓練即受聘的最年輕教授，並擔任首位安進學者（「Amgen Science Fellow」），在 Howard
More news about: 晶泰科技
Jul 02, 2025, 19:34 ET Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Jul 02, 2025, 19:09 ET Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Jul 02, 2025, 19:00 ET Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
without patent extensions. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.